Jafron Deferred Long Term Liab vs Common Stock Analysis

300529 Stock

30.48 0.41 1.36%

Jafron Biomedical financial indicator trend analysis is infinitely more than just investigating Jafron Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jafron Biomedical is a good investment. Please check the relationship between Jafron Biomedical Deferred Long Term Liab and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Deferred Long Term Liab vs Common Stock

Deferred Long Term Liab vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jafron Biomedical Deferred Long Term Liab account and Common Stock. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Jafron Biomedical's Deferred Long Term Liab and Common Stock is 0.89. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Common Stock in the same time period over historical financial statements of Jafron Biomedical Co, assuming nothing else is changed. The correlation between historical values of Jafron Biomedical's Deferred Long Term Liab and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Jafron Biomedical Co are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Deferred Long Term Liab i.e., Jafron Biomedical's Deferred Long Term Liab and Common Stock go up and down completely randomly.

Correlation Coefficient

0.89

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Common Stock

Most indicators from Jafron Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jafron Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Tax Provision is expected to grow to about 119.8 M, whereas Selling General Administrative is forecasted to decline to about 363.6 M.

	2021	2022	2023	2024 (projected)
Operating Income	1.4B	1.0B	523.2M	528.6M
Total Revenue	2.7B	2.5B	1.9B	1.2B

Operating Income Total Revenue

Jafron Biomedical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Retained Earnings	Accounts Payable	Cash	Other Assets	Net Receivables	Inventory	Other Current Assets	Total Liab	Intangible Assets	Common Stock	Property Plant Equipment	Good Will	Net Tangible Assets	Deferred Long Term Liab	Total Current Assets	Non Current Assets Total	Non Currrent Assets Other	Short Term Investments	Non Current Liabilities Total	Common Stock Shares Outstanding	Net Invested Capital
Total Assets		-0.03	0.96	0.89	0.97	0.89	0.95	1.0	0.98	0.71	0.95	0.61	0.94	0.88	0.95	0.99	0.49	0.92	0.97	0.95	0.95	0.87	0.81	0.91	0.68	0.94
Other Current Liab	-0.03		-0.13	0.24	-0.1	0.2	-0.27	0.0	0.02	0.47	-0.31	0.42	-0.28	0.14	0.05	-0.04	0.66	0.15	-0.18	0.07	-0.05	0.34	0.45	-0.35	-0.28	-0.16
Total Current Liabilities	0.96	-0.13		0.78	0.95	0.76	0.98	0.96	0.96	0.51	0.98	0.4	0.97	0.77	0.9	0.95	0.32	0.82	0.93	0.87	0.89	0.79	0.77	0.92	0.74	0.88
Total Stockholder Equity	0.89	0.24	0.78		0.82	0.99	0.75	0.88	0.84	0.86	0.74	0.76	0.71	0.96	0.87	0.88	0.74	0.98	0.82	0.97	0.93	0.89	0.88	0.66	0.3	0.89
Other Liab	0.97	-0.1	0.95	0.82		0.83	0.94	0.97	0.97	0.65	0.95	0.52	0.96	0.82	0.92	0.98	0.38	0.85	0.96	0.9	0.91	0.84	0.74	0.94	0.7	0.92
Retained Earnings	0.89	0.2	0.76	0.99	0.83		0.74	0.87	0.85	0.85	0.75	0.8	0.73	0.98	0.85	0.88	0.72	0.98	0.85	0.97	0.95	0.89	0.85	0.69	0.31	0.92
Accounts Payable	0.95	-0.27	0.98	0.75	0.94	0.74		0.94	0.92	0.48	0.99	0.37	0.97	0.76	0.89	0.94	0.25	0.8	0.93	0.85	0.89	0.73	0.68	0.94	0.74	0.89
Cash	1.0	0.0	0.96	0.88	0.97	0.87	0.94		0.98	0.69	0.95	0.58	0.94	0.86	0.94	0.99	0.47	0.91	0.96	0.94	0.93	0.87	0.82	0.9	0.69	0.92
Other Assets	0.98	0.02	0.96	0.84	0.97	0.85	0.92	0.98		0.68	0.93	0.55	0.95	0.84	0.89	0.96	0.47	0.88	0.95	0.92	0.92	0.91	0.83	0.92	0.68	0.91
Net Receivables	0.71	0.47	0.51	0.86	0.65	0.85	0.48	0.69	0.68		0.47	0.86	0.47	0.78	0.7	0.69	0.85	0.77	0.61	0.78	0.69	0.86	0.71	0.43	0.24	0.67
Inventory	0.95	-0.31	0.98	0.74	0.95	0.75	0.99	0.95	0.93	0.47		0.38	0.99	0.76	0.87	0.94	0.23	0.8	0.96	0.86	0.89	0.73	0.66	0.97	0.75	0.91
Other Current Assets	0.61	0.42	0.4	0.76	0.52	0.8	0.37	0.58	0.55	0.86	0.38		0.38	0.78	0.65	0.63	0.77	0.7	0.59	0.66	0.62	0.67	0.58	0.35	0.22	0.61
Total Liab	0.94	-0.28	0.97	0.71	0.96	0.73	0.97	0.94	0.95	0.47	0.99	0.38		0.74	0.86	0.94	0.2	0.78	0.96	0.85	0.88	0.75	0.65	0.99	0.76	0.9
Intangible Assets	0.88	0.14	0.77	0.96	0.82	0.98	0.76	0.86	0.84	0.78	0.76	0.78	0.74		0.85	0.88	0.68	0.97	0.86	0.96	0.96	0.85	0.83	0.7	0.31	0.93
Common Stock	0.95	0.05	0.9	0.87	0.92	0.85	0.89	0.94	0.89	0.7	0.87	0.65	0.86	0.85		0.96	0.47	0.88	0.89	0.89	0.87	0.78	0.77	0.81	0.64	0.86
Property Plant Equipment	0.99	-0.04	0.95	0.88	0.98	0.88	0.94	0.99	0.96	0.69	0.94	0.63	0.94	0.88	0.96		0.47	0.91	0.98	0.93	0.94	0.84	0.78	0.91	0.69	0.93
Good Will	0.49	0.66	0.32	0.74	0.38	0.72	0.25	0.47	0.47	0.85	0.23	0.77	0.2	0.68	0.47	0.47		0.65	0.37	0.59	0.53	0.71	0.71	0.13	0.0	0.45
Net Tangible Assets	0.92	0.15	0.82	0.98	0.85	0.98	0.8	0.91	0.88	0.77	0.8	0.7	0.78	0.97	0.88	0.91	0.65		0.86	0.98	0.97	0.87	0.89	0.74	0.34	0.93
Deferred Long Term Liab	0.97	-0.18	0.93	0.82	0.96	0.85	0.93	0.96	0.95	0.61	0.96	0.59	0.96	0.86	0.89	0.98	0.37	0.86		0.91	0.93	0.79	0.7	0.94	0.71	0.95
Total Current Assets	0.95	0.07	0.87	0.97	0.9	0.97	0.85	0.94	0.92	0.78	0.86	0.66	0.85	0.96	0.89	0.93	0.59	0.98	0.91		0.98	0.9	0.85	0.81	0.43	0.96
Non Current Assets Total	0.95	-0.05	0.89	0.93	0.91	0.95	0.89	0.93	0.92	0.69	0.89	0.62	0.88	0.96	0.87	0.94	0.53	0.97	0.93	0.98		0.86	0.82	0.85	0.45	0.99
Non Currrent Assets Other	0.87	0.34	0.79	0.89	0.84	0.89	0.73	0.87	0.91	0.86	0.73	0.67	0.75	0.85	0.78	0.84	0.71	0.87	0.79	0.9	0.86		0.89	0.7	0.42	0.82
Short Term Investments	0.81	0.45	0.77	0.88	0.74	0.85	0.68	0.82	0.83	0.71	0.66	0.58	0.65	0.83	0.77	0.78	0.71	0.89	0.7	0.85	0.82	0.89		0.58	0.3	0.73
Non Current Liabilities Total	0.91	-0.35	0.92	0.66	0.94	0.69	0.94	0.9	0.92	0.43	0.97	0.35	0.99	0.7	0.81	0.91	0.13	0.74	0.94	0.81	0.85	0.7	0.58		0.76	0.89
Common Stock Shares Outstanding	0.68	-0.28	0.74	0.3	0.7	0.31	0.74	0.69	0.68	0.24	0.75	0.22	0.76	0.31	0.64	0.69	0.0	0.34	0.71	0.43	0.45	0.42	0.3	0.76		0.49
Net Invested Capital	0.94	-0.16	0.88	0.89	0.92	0.92	0.89	0.92	0.91	0.67	0.91	0.61	0.9	0.93	0.86	0.93	0.45	0.93	0.95	0.96	0.99	0.82	0.73	0.89	0.49

Click cells to compare fundamentals

Jafron Biomedical Account Relationship Matchups

Jafron Biomedical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.5B	3.2B	4.8B	5.4B	5.5B	5.8B
Other Current Liab	131.8M	140.8M	129.3M	5.5M	4.9M	4.6M
Total Current Liabilities	262.6M	330.8M	386.3M	717.2M	829.4M	870.9M
Total Stockholder Equity	2.1B	2.8B	3.4B	3.6B	3.1B	1.8B
Other Liab	51.1M	61.5M	52.2M	125.8M	144.7M	151.9M
Retained Earnings	1.2B	1.7B	2.3B	2.1B	2.0B	1.0B
Accounts Payable	32.8M	50.2M	60.8M	128.5M	135.6M	142.4M
Cash	1.3B	1.6B	2.3B	2.6B	2.8B	3.0B
Other Assets	107.9M	102.4M	91.6M	225.4M	259.2M	272.2M
Net Receivables	169.8M	167.4M	314.4M	221.7M	74.9M	118.9M
Inventory	92.3M	120.7M	196.5M	349.1M	385.0M	404.2M
Other Current Assets	25.9M	65.3M	75.3M	35.6M	17.3M	26.1M
Total Liab	324.1M	383.1M	1.4B	1.8B	2.4B	2.5B
Intangible Assets	48.1M	89.9M	101.3M	100.4M	100.4M	53.5M
Common Stock	417.3M	418.7M	799.1M	805.5M	926.3M	972.6M
Property Plant Equipment	457.6M	639.6M	905.5M	1.3B	1.5B	1.5B
Net Tangible Assets	1.6B	2.1B	2.7B	3.2B	3.7B	2.0B
Deferred Long Term Liab	3.4M	14.8M	20.4M	36.0M	41.3M	43.4M
Total Current Assets	1.6B	2.0B	3.1B	3.3B	3.3B	2.1B
Non Current Assets Total	934.9M	1.2B	1.8B	2.1B	2.2B	1.3B
Non Currrent Assets Other	77.5M	58.2M	162.8M	148.2M	107.0M	102.3M
Non Current Liabilities Total	61.5M	52.2M	1.0B	1.1B	1.6B	1.6B
Common Stock Shares Outstanding	795.5M	799.1M	805.5M	807.7M	807.6M	880.0M
Net Invested Capital	2.1B	2.8B	4.3B	4.8B	4.8B	3.4B
Net Working Capital	1.3B	1.7B	2.7B	2.6B	2.5B	2.0B
Capital Stock	418.7M	799.1M	805.5M	807.7M	807.6M	743.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Jafron Stock

Balance Sheet is a snapshot of the financial position of Jafron Biomedical at a specified time, usually calculated after every quarter, six months, or one year. Jafron Biomedical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jafron Biomedical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jafron currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jafron Deferred Long Term Liab vs Common Stock Analysis

Deferred Long Term Liab vs Common Stock

Deferred Long Term Liab vs Common Stock Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Common Stock

Jafron Biomedical fundamental ratios Correlations

Jafron Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jafron Biomedical fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Jafron Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Property Plant Equipment	+ 0.99	Total Assets
Retained Earnings	+ 0.99	Total Stockholder Equity
Inventory	+ 0.99	Accounts Payable
Property Plant Equipment	+ 0.99	Cash
Total Liab	+ 0.99	Inventory

Non Current Liabilities Total	- 0.35	Other Current Liab
Inventory	- 0.31	Other Current Liab
Common Stock Shares Outstanding	- 0.28	Other Current Liab
Total Liab	- 0.28	Other Current Liab
Accounts Payable	- 0.27	Other Current Liab
Deferred Long Term Liab	- 0.18	Other Current Liab